These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8237091)

  • 1. [p53 and hepatocellular carcinomas].
    Mihm S; Leonhardt U; Ramadori G
    Z Gastroenterol; 1993 Sep; 31(9):498-9. PubMed ID: 8237091
    [No Abstract]   [Full Text] [Related]  

  • 2. Aflatoxins as a cause of hepatocellular carcinoma.
    Kew MC
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):305-10. PubMed ID: 24078988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
    Dong-Dong L; Xi-Ran Z
    Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and p21WAF1/CIP1 in hepatitis B virus related hepatocarcinogenesis.
    Park YN; Chae KJ; Kwon KW; Oh BK; Lee KS; Lee WJ; Park C
    Hepatogastroenterology; 2003; 50(53):1292-6. PubMed ID: 14571721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutation in hepatocellular carcinoma and chronic liver disease.
    Ceyhan K; Akpolat I; Bozdoğan N; Kobat I; Ekinci C
    Am J Gastroenterol; 1996 Jul; 91(7):1476-7. PubMed ID: 8678035
    [No Abstract]   [Full Text] [Related]  

  • 6. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT; Lung ML
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas.
    Shi YZ; Hui AM; Takayama T; Li X; Cui X; Makuuchi M
    Br J Cancer; 2000 Jul; 83(1):50-5. PubMed ID: 10883667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas.
    Ito T; Nishida N; Fukuda Y; Nishimura T; Komeda T; Nakao K
    J Gastroenterol; 2004; 39(4):355-61. PubMed ID: 15168247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
    Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
    Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma.
    Yuwen H; Hsia CC; Nakashima Y; Evangelista A; Tabor E
    Biochem Biophys Res Commun; 1997 May; 234(1):194-7. PubMed ID: 9168988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
    Kiss A; Wang NJ; Xie JP; Thorgeirsson SS
    Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
    Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
    J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sequence alterations in p53 gene of hepatocellular carcinoma from high aflatoxin risk area in Guangxi].
    Deng Z; Pan L; Ma Y
    Zhonghua Zhong Liu Za Zhi; 1997 Jan; 19(1):18-21. PubMed ID: 10743047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
    Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
    Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
    Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
    Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 codon 249 mutation in hepatocellular carcinomas from Nigeria.
    Ndububa DA; Yakicier CM; Ojo OS; Adeodu OO; Rotimi O; Ogunbiyi O; Ozturk M
    Afr J Med Med Sci; 2001; 30(1-2):125-7. PubMed ID: 14510167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma.
    Itoh T; Shiro T; Seki T; Nakagawa T; Wakabayashi M; Inoue K; Okamura A
    Int J Mol Med; 2000 Aug; 6(2):137-42. PubMed ID: 10891556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation.
    Gursoy-Yuzugullu O; Yuzugullu H; Yilmaz M; Ozturk M
    Liver Int; 2011 Apr; 31(4):561-71. PubMed ID: 21382167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.